Therapeutic Approach

Archive: May, 2017

Ritter Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Updates

LOS ANGELES (May 9, 2017) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a leading developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today reported financial results for the first quarter ended March 31, 2017 and provided other business updates. Recent Highlights Clinical microbiome data […]

Leave Your Comments »

Ritter Pharmaceuticals Announces Issuance of New Patents for its Lactose Intolerance Treatment, RP-G28, and Provides an Update on its Path Forward into Phase 3

LOS ANGELES (May 2, 2017) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a leading developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that it has been issued three new patents directed to its development compound RP-G28.  The Company is also providing an […]

Leave Your Comments »

Featuring Recent Posts WordPress Widget development by YD